BTIG Downgrades AVITA Medical to Neutral
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman has downgraded AVITA Medical (NASDAQ:RCEL) from Buy to Neutral, indicating a shift in the firm's outlook on the company's stock.
April 11, 2024 | 10:53 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AVITA Medical was downgraded by BTIG analyst Ryan Zimmerman from Buy to Neutral, potentially impacting investor sentiment and the stock's performance.
Analyst downgrades typically lead to a negative short-term reaction in the stock market as they suggest a less favorable outlook on the company's future performance. Given the downgrade from Buy to Neutral, it's likely that investor sentiment around AVITA Medical may become more cautious, potentially leading to a decrease in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100